Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
Pre-publication versions of this article are available by contacting email@example.com.
|20 Aug 2018||Submitted||Original manuscript|
|23 Sep 2018||Reviewed||Reviewer Report - Renata Duchnowska|
|3 Oct 2018||Reviewed||Reviewer Report - Judith Bliss|
|12 Oct 2018||Author responded||Author comments - Joaquín Gavila|
|Resubmission - Version 2|
|12 Oct 2018||Submitted||Manuscript version 2|
|1 Nov 2018||Reviewed||Reviewer Report - Judith Bliss|
|12 Nov 2018||Author responded||Author comments - Joaquín Gavila|
|Resubmission - Version 3|
|12 Nov 2018||Submitted||Manuscript version 3|
|10 Dec 2018||Editorially accepted|
|9 Jan 2019||Article published||10.1186/s12916-018-1233-1|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting firstname.lastname@example.org.
You can find further information about the peer review system here.